Medical Condition News

RSS

NARSAD awards $12.6 million for mental health research

NARSAD: The Brain and Behavior Research Fund awards $12.6 million in new research grants, strengthening its investment in the most promising ideas to lead to breakthroughs in understanding and treating mental illness.

7 Jan 2011

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Virdante Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted a key patent that supports the Company's "Sialic Switch" technology for improving the anti-inflammatory activity of antibody-based drugs to treat autoimmune and inflammatory disorders.

7 Jan 2011

Research provides new insights into eating disorders in Native Americans

The research, published in the International Journal of Eating Disorders, provides new insights into the extent to which Native American populations experience eating disorders, revealing that women are more likely to report behavioral symptoms then men, while challenging views that NA men and ethnically white men will experience different psychological symptoms.

7 Jan 2011

New research: NFKBIA gene loss induces glioblastoma development

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Researchers discover specific genetic abnormalities in hESC, iPSC lines

A multinational team of researchers led by stem cell scientists at the University of California, San Diego School of Medicine and Scripps Research Institute has documented specific genetic abnormalities that occur in human embryonic and induced pluripotent stem cell lines.

7 Jan 2011

CeNeRx commences TriRima Phase II trial for treatment resistant depression

CeNeRx BioPharma, today reported that it has initiated a Phase II trial of its new formulation of TriRima, the company's novel antidepressant in development as monotherapy for treatment resistant depression.

7 Jan 2011

Researchers develop simple blood test to track Alzheimer's disease

Using a new technology that relies on thousands of synthetic molecules to fish for disease-specific antibodies, researchers have developed a potential method for detecting Alzheimer's disease with a simple blood test.

6 Jan 2011

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

6 Jan 2011

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy, a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

6 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Urine tests could detect Obsessive Compulsive Disorder

Australian researchers have found a novel and easy way to detect a common and debilitating anxiety disorder called the Obsessive Compulsive Disorder or OCD. Scientists at the Centenary Institute in Sydney discovered a gene responsible for a rare kidney disorder is also behind OCD. This may make detecting OCD easier through a simple urine test. This test could also identify babies with risk of early-onset OCD. OCD affects up to 3 per cent of all Australians and in its worst cases can be completely debilitating, causing people to have to stay at home. OCD sufferers feel intense anxiety and are compelled to practice rituals - such as hand washing or arranging objects.

6 Jan 2011

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Scientists develop novel technology to detect immune molecules specific to Alzheimer's disease

Scientists from the Florida campus of The Scripps Research Institute, have developed a novel technology that is able to detect the presence of immune molecules specific to Alzheimer's disease in patients' blood samples. While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.

6 Jan 2011

Presence of PML molecules could serve to diagnose condition of tumor: Researchers

Cancer cells reproduce by dividing in two, but a molecule known as PML limits how many times this can happen, according to researchers lead by Dr. Gerardo Ferbeyre of the University of Montreal's Department of Biochemistry.

6 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

Medical Condition News

NARSAD awards $12.6 million for mental health research

X-BODY BioSciences, Mercator Therapeutics collaborate for multi-target cancer research

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Virdante Pharmaceuticals receives US key patent for Sialic Switch technology

Research provides new insights into eating disorders in Native Americans

New research: NFKBIA gene loss induces glioblastoma development

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers discover specific genetic abnormalities in hESC, iPSC lines

CeNeRx commences TriRima Phase II trial for treatment resistant depression

Researchers develop simple blood test to track Alzheimer's disease

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Acceleron recieves $1.5 million MDA grant for ACE-031 clinical study in Duchenne Muscular Dystrophy

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Urine tests could detect Obsessive Compulsive Disorder

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Scientists develop novel technology to detect immune molecules specific to Alzheimer's disease

Presence of PML molecules could serve to diagnose condition of tumor: Researchers

New technique to analyze and quantify changes in protein

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News